Phase Ib and pharmacokinetics study of alpelisib, a PIK3CA inhibitor, and capecitabine in patients with advanced solid tumors
BackgroundThis phase Ib study was performed to determine the safety of combination capecitabine with alpleisib (phosphatidylinositol 3-kinase catalytic subunit p110α blockade) and determine the maximal tolerated dose (MTD) and recommended phase ll dose (RP2D) of this combination regimen in patients...
שמור ב:
| Principais autores: | , , , , , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Frontiers Media S.A.
2024-07-01
|
| סדרה: | Frontiers in Oncology |
| נושאים: | |
| גישה מקוונת: | https://www.frontiersin.org/articles/10.3389/fonc.2024.1390452/full |
| תגים: |
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|